Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611000666921
Ethics application status
Approved
Date submitted
23/05/2011
Date registered
1/07/2011
Date last updated
17/11/2024
Date data sharing statement initially provided
17/11/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
Gabapentin for taxane associated acute pain syndrome - randomised, placebo-controlled, crossover trial. The TAPS Trial
Scientific title
In patients receiving docetaxel for early stage breast cancer who experience taxane associated acute pain syndrome is gabapentin better than placebo
for reducing pain?
Secondary ID [1] 260056 0
Nil
Universal Trial Number (UTN)
U1111-1120-9453
Trial acronym
The TAPS Trial
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast cancer 265721 0
Taxane associated acute pain syndrome 267957 0
Condition category
Condition code
Cancer 265863 265863 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Gabapentin 300mg three times a day, orally. Starting the day before chemotherapy, for 6 days in total. The chemotherapy is given every three weeks thus there will be a three week wash out period between the intervention and placebo arms. The expected time of elimination of gabapentin is 31.5 hours.
Intervention code [1] 264473 0
Treatment: Drugs
Comparator / control treatment
Placebo, Microcrystalline Cellulose
Control group
Placebo

Outcomes
Primary outcome [1] 266817 0
To determine the effects of gabapentin on patient reported worst pain score (pain that is new since your last dose of chemotherapy) using a numeric rating scale
Timepoint [1] 266817 0
Daily for a week after chemotherapy
Secondary outcome [1] 276105 0
To determine the effects of gabapentin on patient reported average pain score, (pain that is new since your last dose of chemotherapy) on a numeric rating scale
Timepoint [1] 276105 0
Daily for a week after chemotherapy
Secondary outcome [2] 276106 0
To determine the effects of gabapentin on usage of other analgesia as reported by the patient
Timepoint [2] 276106 0
During the 3 weeks after chemotherapy
Secondary outcome [3] 276441 0
To determine the effects of gabapentin on adverse events measured by common terminology for adverse events. Particular adverse events for review include pain (pain- other, muscle and joint aches and pains), nausea, fatigue, insomnia, somnolence and dizziness.
Timepoint [3] 276441 0
Daily for a week after chemotherapy
Secondary outcome [4] 276442 0
To determine the effects of gabapentin on patient preference as reported by the patient
Timepoint [4] 276442 0
3 months after the start of chemotherapy.
Secondary outcome [5] 276483 0
To determine the effects of gabapentin on aspects of health related quality of life using 'Patient's Disease and Treatment Assessment Form'
Timepoint [5] 276483 0
At end of week one after each cycle of chemotherpay and at 3 months after the start of chemotherapy.
Secondary outcome [6] 276484 0
Correlative outcome. Patient description of pain using a pain assessment questionniare (specific to taxane pain, from the Mayo clinic)
Timepoint [6] 276484 0
One week after cycle one docetaxel.

Eligibility
Key inclusion criteria
Patients with histologically confirmed adenocarcinoma of the breast who have completed definitive surgery and meet the following criteria
1. Planned and agreeable to treatment with docetaxel 100mg/m2 3 weekly as part of the regimen FEC-
D for early stage breast cancer
2. Adequate organ function for the planned chemotherapy
3. Creatinine clearance of >50ml/min by estimated glomerular filtraiton rate
4. Ages 18 years or over
5. Able to give informed consent
6. Received no prior taxane chemotherapy
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Score of 4 or more for ‘pain on average over the last 24 hours” on day prior to cycle 1 docetaxel (i.e.
pre existing pain)
2. Regular use of analgesia (other than for post operative pain)
3. Epilepsy or seizure disorder
4. Metastatic disease

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by phone
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation using a randomisation table generated by computer software
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 3
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Data collected is being analysed
Reason for early stopping/withdrawal
Participant recruitment difficulties
Date of first participant enrolment
Anticipated
1/07/2011
Actual
2/01/2012
Date of last participant enrolment
Anticipated
Actual
1/08/2018
Date of last data collection
Anticipated
1/01/2020
Actual
Sample size
Target
126
Accrual to date
Final
42
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment postcode(s) [1] 4037 0
4029
Recruitment postcode(s) [2] 4038 0
4560
Recruitment postcode(s) [3] 4039 0
4101
Recruitment postcode(s) [4] 4040 0
1402
Recruitment postcode(s) [5] 4041 0
4215
Recruitment postcode(s) [6] 4042 0
4020

Funding & Sponsors
Funding source category [1] 267121 0
Hospital
Name [1] 267121 0
Sunshine Coast Cancer Centre, Nambour General Hospital
Country [1] 267121 0
Australia
Primary sponsor type
Hospital
Name
Sunshine Coast Cancer Centre, Nambour General Hospital
Address
Hospital Road,
Nambour
QLD
4560
Country
Australia
Secondary sponsor category [1] 264202 0
None
Name [1] 264202 0
Address [1] 264202 0
Country [1] 264202 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 267107 0
Metro North Health Human Research Ethics Committee A
Ethics committee address [1] 267107 0
Ethics committee country [1] 267107 0
Australia
Date submitted for ethics approval [1] 267107 0
30/05/2011
Approval date [1] 267107 0
03/10/2011
Ethics approval number [1] 267107 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 32531 0
Dr Kathleen Houston
Address 32531 0
Sunshine Coast University Hospital
6 Doherty Street
Birtinya
QLD 4575
Country 32531 0
Australia
Phone 32531 0
+61 752020000
Fax 32531 0
Email 32531 0
Kathleen.houston@health.qld.gov.au
Contact person for public queries
Name 15778 0
Christine Cocks
Address 15778 0
Cancer Care Trials
Sunshine Coast University Hospital
6 Doherty Street
Birtinya
QLD 4575
Country 15778 0
Australia
Phone 15778 0
+61 752020000
Fax 15778 0
+61 7 5470 6343
Email 15778 0
Christine.cocks@health.qld.gov.au
Contact person for scientific queries
Name 6706 0
Dr Kathleen Houston
Address 6706 0
Sunshine Coast University Hospital
6 Doherty Street
Birtinya
QLD 4575
Country 6706 0
Australia
Phone 6706 0
+61 752020000
Fax 6706 0
+61732522746
Email 6706 0
Sunshine Coast University Hospital 6 Doherty Street Birtinya QLD 4575

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.